nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—CYP2A6—Fluorouracil—head and neck cancer	0.325	0.407	CbGbCtD
Arformoterol—CYP2D6—Hydroxyurea—head and neck cancer	0.267	0.335	CbGbCtD
Arformoterol—CYP2C9—Fluorouracil—head and neck cancer	0.112	0.14	CbGbCtD
Arformoterol—CYP2D6—Vinblastine—head and neck cancer	0.0947	0.118	CbGbCtD
Arformoterol—Isoprenaline—MAPK1—head and neck cancer	0.0111	0.823	CrCbGaD
Arformoterol—Carcinoma of lung—Docetaxel—head and neck cancer	0.00952	0.0511	CcSEcCtD
Arformoterol—Lung neoplasm malignant—Docetaxel—head and neck cancer	0.00823	0.0441	CcSEcCtD
Arformoterol—Lower respiratory tract infection—Docetaxel—head and neck cancer	0.00483	0.0259	CcSEcCtD
Arformoterol—Atrial flutter—Docetaxel—head and neck cancer	0.00434	0.0233	CcSEcCtD
Arformoterol—Rectal haemorrhage—Vinblastine—head and neck cancer	0.00386	0.0207	CcSEcCtD
Arformoterol—Neoplasm—Vinblastine—head and neck cancer	0.00315	0.0169	CcSEcCtD
Arformoterol—Neoplasm—Hydroxyurea—head and neck cancer	0.00287	0.0154	CcSEcCtD
Arformoterol—Oral candidiasis—Docetaxel—head and neck cancer	0.0026	0.0139	CcSEcCtD
Arformoterol—Supraventricular tachycardia—Docetaxel—head and neck cancer	0.00252	0.0135	CcSEcCtD
Arformoterol—Herpes simplex—Fluorouracil—head and neck cancer	0.00248	0.0133	CcSEcCtD
Arformoterol—Leukocytosis—Fluorouracil—head and neck cancer	0.00243	0.0131	CcSEcCtD
Arformoterol—Isoprenaline—CYP1A1—head and neck cancer	0.00239	0.177	CrCbGaD
Arformoterol—Inflammation—Fluorouracil—head and neck cancer	0.00236	0.0127	CcSEcCtD
Arformoterol—Dermatitis contact—Fluorouracil—head and neck cancer	0.00226	0.0121	CcSEcCtD
Arformoterol—Angina pectoris—Vinblastine—head and neck cancer	0.00213	0.0114	CcSEcCtD
Arformoterol—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00192	0.0103	CcSEcCtD
Arformoterol—Myocardial infarction—Vinblastine—head and neck cancer	0.00191	0.0103	CcSEcCtD
Arformoterol—Bone disorder—Docetaxel—head and neck cancer	0.00183	0.00981	CcSEcCtD
Arformoterol—Pharyngitis—Vinblastine—head and neck cancer	0.00174	0.00932	CcSEcCtD
Arformoterol—Inflammation—Docetaxel—head and neck cancer	0.0017	0.00913	CcSEcCtD
Arformoterol—Blood pressure increased—Docetaxel—head and neck cancer	0.00165	0.00886	CcSEcCtD
Arformoterol—Candida infection—Docetaxel—head and neck cancer	0.00158	0.00846	CcSEcCtD
Arformoterol—Dry skin—Fluorouracil—head and neck cancer	0.00152	0.00817	CcSEcCtD
Arformoterol—Neoplasm—Docetaxel—head and neck cancer	0.00149	0.00801	CcSEcCtD
Arformoterol—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00148	0.00797	CcSEcCtD
Arformoterol—Ill-defined disorder—Vinblastine—head and neck cancer	0.00141	0.00758	CcSEcCtD
Arformoterol—Angina pectoris—Fluorouracil—head and neck cancer	0.0014	0.0075	CcSEcCtD
Arformoterol—Malaise—Vinblastine—head and neck cancer	0.00137	0.00737	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00133	0.00716	CcSEcCtD
Arformoterol—Cardiac failure congestive—Docetaxel—head and neck cancer	0.00132	0.00709	CcSEcCtD
Arformoterol—Hypertension—Vinblastine—head and neck cancer	0.00132	0.00706	CcSEcCtD
Arformoterol—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.00129	0.00692	CcSEcCtD
Arformoterol—Discomfort—Vinblastine—head and neck cancer	0.00128	0.00687	CcSEcCtD
Arformoterol—Atrial fibrillation—Docetaxel—head and neck cancer	0.00126	0.00679	CcSEcCtD
Arformoterol—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00126	0.00677	CcSEcCtD
Arformoterol—Myocardial infarction—Fluorouracil—head and neck cancer	0.00125	0.00673	CcSEcCtD
Arformoterol—Malaise—Hydroxyurea—head and neck cancer	0.00125	0.00672	CcSEcCtD
Arformoterol—Urinary tract infection—Fluorouracil—head and neck cancer	0.00124	0.00667	CcSEcCtD
Arformoterol—Conjunctivitis—Fluorouracil—head and neck cancer	0.00124	0.00667	CcSEcCtD
Arformoterol—Sinusitis—Fluorouracil—head and neck cancer	0.0012	0.00644	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00117	0.0063	CcSEcCtD
Arformoterol—Discomfort—Hydroxyurea—head and neck cancer	0.00117	0.00627	CcSEcCtD
Arformoterol—Rhinitis—Fluorouracil—head and neck cancer	0.00115	0.00618	CcSEcCtD
Arformoterol—Pharyngitis—Fluorouracil—head and neck cancer	0.00114	0.00612	CcSEcCtD
Arformoterol—Oedema—Hydroxyurea—head and neck cancer	0.00113	0.00608	CcSEcCtD
Arformoterol—Infection—Hydroxyurea—head and neck cancer	0.00113	0.00604	CcSEcCtD
Arformoterol—Dehydration—Docetaxel—head and neck cancer	0.00111	0.00598	CcSEcCtD
Arformoterol—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00111	0.00597	CcSEcCtD
Arformoterol—Skin disorder—Hydroxyurea—head and neck cancer	0.0011	0.00591	CcSEcCtD
Arformoterol—Dry skin—Docetaxel—head and neck cancer	0.0011	0.00589	CcSEcCtD
Arformoterol—Cramp muscle—Docetaxel—head and neck cancer	0.00108	0.00579	CcSEcCtD
Arformoterol—Nasopharyngitis—Docetaxel—head and neck cancer	0.00107	0.00575	CcSEcCtD
Arformoterol—Constipation—Vinblastine—head and neck cancer	0.00106	0.0057	CcSEcCtD
Arformoterol—Pain—Vinblastine—head and neck cancer	0.00106	0.0057	CcSEcCtD
Arformoterol—Arrhythmia—Fluorouracil—head and neck cancer	0.00103	0.00551	CcSEcCtD
Arformoterol—Feeling abnormal—Vinblastine—head and neck cancer	0.00102	0.0055	CcSEcCtD
Arformoterol—Bronchospasm—Docetaxel—head and neck cancer	0.00102	0.00547	CcSEcCtD
Arformoterol—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00102	0.00545	CcSEcCtD
Arformoterol—Dyspnoea—Hydroxyurea—head and neck cancer	0.00101	0.00542	CcSEcCtD
Arformoterol—Angina pectoris—Docetaxel—head and neck cancer	0.00101	0.00541	CcSEcCtD
Arformoterol—Somnolence—Hydroxyurea—head and neck cancer	0.00101	0.00541	CcSEcCtD
Arformoterol—Dyspepsia—Hydroxyurea—head and neck cancer	0.000998	0.00535	CcSEcCtD
Arformoterol—Abdominal pain—Vinblastine—head and neck cancer	0.000983	0.00527	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000979	0.00525	CcSEcCtD
Arformoterol—Fatigue—Hydroxyurea—head and neck cancer	0.000978	0.00524	CcSEcCtD
Arformoterol—Pain—Hydroxyurea—head and neck cancer	0.00097	0.0052	CcSEcCtD
Arformoterol—Constipation—Hydroxyurea—head and neck cancer	0.00097	0.0052	CcSEcCtD
Arformoterol—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000934	0.00501	CcSEcCtD
Arformoterol—Hypersensitivity—Vinblastine—head and neck cancer	0.000916	0.00491	CcSEcCtD
Arformoterol—Acute coronary syndrome—Docetaxel—head and neck cancer	0.00091	0.00488	CcSEcCtD
Arformoterol—Myocardial infarction—Docetaxel—head and neck cancer	0.000905	0.00486	CcSEcCtD
Arformoterol—Conjunctivitis—Docetaxel—head and neck cancer	0.000898	0.00482	CcSEcCtD
Arformoterol—Body temperature increased—Hydroxyurea—head and neck cancer	0.000896	0.00481	CcSEcCtD
Arformoterol—Asthenia—Vinblastine—head and neck cancer	0.000892	0.00479	CcSEcCtD
Arformoterol—Myalgia—Fluorouracil—head and neck cancer	0.000851	0.00457	CcSEcCtD
Arformoterol—Chest pain—Fluorouracil—head and neck cancer	0.000851	0.00457	CcSEcCtD
Arformoterol—Diarrhoea—Vinblastine—head and neck cancer	0.000851	0.00456	CcSEcCtD
Arformoterol—Discomfort—Fluorouracil—head and neck cancer	0.000841	0.00451	CcSEcCtD
Arformoterol—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000835	0.00448	CcSEcCtD
Arformoterol—Rhinitis—Docetaxel—head and neck cancer	0.000831	0.00446	CcSEcCtD
Arformoterol—Pharyngitis—Docetaxel—head and neck cancer	0.000823	0.00441	CcSEcCtD
Arformoterol—Dizziness—Vinblastine—head and neck cancer	0.000822	0.00441	CcSEcCtD
Arformoterol—Urinary tract disorder—Docetaxel—head and neck cancer	0.000819	0.00439	CcSEcCtD
Arformoterol—Oedema peripheral—Docetaxel—head and neck cancer	0.000817	0.00438	CcSEcCtD
Arformoterol—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000816	0.00438	CcSEcCtD
Arformoterol—Oedema—Fluorouracil—head and neck cancer	0.000816	0.00438	CcSEcCtD
Arformoterol—Connective tissue disorder—Docetaxel—head and neck cancer	0.000815	0.00437	CcSEcCtD
Arformoterol—Asthenia—Hydroxyurea—head and neck cancer	0.000813	0.00436	CcSEcCtD
Arformoterol—Urethral disorder—Docetaxel—head and neck cancer	0.000813	0.00436	CcSEcCtD
Arformoterol—Infection—Fluorouracil—head and neck cancer	0.000811	0.00435	CcSEcCtD
Arformoterol—Nervous system disorder—Fluorouracil—head and neck cancer	0.0008	0.00429	CcSEcCtD
Arformoterol—Visual impairment—Docetaxel—head and neck cancer	0.000799	0.00429	CcSEcCtD
Arformoterol—Tachycardia—Fluorouracil—head and neck cancer	0.000796	0.00427	CcSEcCtD
Arformoterol—Vomiting—Vinblastine—head and neck cancer	0.00079	0.00424	CcSEcCtD
Arformoterol—Headache—Vinblastine—head and neck cancer	0.000779	0.00418	CcSEcCtD
Arformoterol—Diarrhoea—Hydroxyurea—head and neck cancer	0.000776	0.00416	CcSEcCtD
Arformoterol—Cardiac disorder—Docetaxel—head and neck cancer	0.000769	0.00413	CcSEcCtD
Arformoterol—Hypotension—Fluorouracil—head and neck cancer	0.000763	0.00409	CcSEcCtD
Arformoterol—Dizziness—Hydroxyurea—head and neck cancer	0.00075	0.00402	CcSEcCtD
Arformoterol—Immune system disorder—Docetaxel—head and neck cancer	0.000749	0.00402	CcSEcCtD
Arformoterol—Mediastinal disorder—Docetaxel—head and neck cancer	0.000747	0.00401	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000744	0.00399	CcSEcCtD
Arformoterol—Arrhythmia—Docetaxel—head and neck cancer	0.000741	0.00397	CcSEcCtD
Arformoterol—Nausea—Vinblastine—head and neck cancer	0.000738	0.00396	CcSEcCtD
Arformoterol—Insomnia—Fluorouracil—head and neck cancer	0.000738	0.00396	CcSEcCtD
Arformoterol—Dyspnoea—Fluorouracil—head and neck cancer	0.000728	0.0039	CcSEcCtD
Arformoterol—Mental disorder—Docetaxel—head and neck cancer	0.000726	0.0039	CcSEcCtD
Arformoterol—Somnolence—Fluorouracil—head and neck cancer	0.000726	0.00389	CcSEcCtD
Arformoterol—Malnutrition—Docetaxel—head and neck cancer	0.000722	0.00387	CcSEcCtD
Arformoterol—Vomiting—Hydroxyurea—head and neck cancer	0.000721	0.00387	CcSEcCtD
Arformoterol—Dyspepsia—Fluorouracil—head and neck cancer	0.000718	0.00385	CcSEcCtD
Arformoterol—Rash—Hydroxyurea—head and neck cancer	0.000715	0.00384	CcSEcCtD
Arformoterol—Dermatitis—Hydroxyurea—head and neck cancer	0.000714	0.00383	CcSEcCtD
Arformoterol—Headache—Hydroxyurea—head and neck cancer	0.00071	0.00381	CcSEcCtD
Arformoterol—Dysgeusia—Docetaxel—head and neck cancer	0.000707	0.00379	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000705	0.00378	CcSEcCtD
Arformoterol—Back pain—Docetaxel—head and neck cancer	0.000698	0.00375	CcSEcCtD
Arformoterol—Pain—Fluorouracil—head and neck cancer	0.000698	0.00374	CcSEcCtD
Arformoterol—Muscle spasms—Docetaxel—head and neck cancer	0.000694	0.00372	CcSEcCtD
Arformoterol—Nausea—Hydroxyurea—head and neck cancer	0.000673	0.00361	CcSEcCtD
Arformoterol—Feeling abnormal—Fluorouracil—head and neck cancer	0.000673	0.00361	CcSEcCtD
Arformoterol—Urticaria—Fluorouracil—head and neck cancer	0.000648	0.00348	CcSEcCtD
Arformoterol—Body temperature increased—Fluorouracil—head and neck cancer	0.000645	0.00346	CcSEcCtD
Arformoterol—Palpitations—Docetaxel—head and neck cancer	0.000638	0.00342	CcSEcCtD
Arformoterol—Cough—Docetaxel—head and neck cancer	0.00063	0.00338	CcSEcCtD
Arformoterol—Hypertension—Docetaxel—head and neck cancer	0.000623	0.00334	CcSEcCtD
Arformoterol—Arthralgia—Docetaxel—head and neck cancer	0.000614	0.0033	CcSEcCtD
Arformoterol—Myalgia—Docetaxel—head and neck cancer	0.000614	0.0033	CcSEcCtD
Arformoterol—Chest pain—Docetaxel—head and neck cancer	0.000614	0.0033	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00061	0.00327	CcSEcCtD
Arformoterol—Hypersensitivity—Fluorouracil—head and neck cancer	0.000601	0.00323	CcSEcCtD
Arformoterol—Dry mouth—Docetaxel—head and neck cancer	0.000601	0.00322	CcSEcCtD
Arformoterol—Oedema—Docetaxel—head and neck cancer	0.000589	0.00316	CcSEcCtD
Arformoterol—Anaphylactic shock—Docetaxel—head and neck cancer	0.000589	0.00316	CcSEcCtD
Arformoterol—Infection—Docetaxel—head and neck cancer	0.000585	0.00314	CcSEcCtD
Arformoterol—Nervous system disorder—Docetaxel—head and neck cancer	0.000578	0.0031	CcSEcCtD
Arformoterol—Pruritus—Fluorouracil—head and neck cancer	0.000577	0.0031	CcSEcCtD
Arformoterol—Tachycardia—Docetaxel—head and neck cancer	0.000575	0.00308	CcSEcCtD
Arformoterol—Skin disorder—Docetaxel—head and neck cancer	0.000572	0.00307	CcSEcCtD
Arformoterol—Diarrhoea—Fluorouracil—head and neck cancer	0.000558	0.003	CcSEcCtD
Arformoterol—Hypotension—Docetaxel—head and neck cancer	0.00055	0.00295	CcSEcCtD
Arformoterol—Dizziness—Fluorouracil—head and neck cancer	0.00054	0.0029	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000537	0.00288	CcSEcCtD
Arformoterol—Insomnia—Docetaxel—head and neck cancer	0.000533	0.00286	CcSEcCtD
Arformoterol—Dyspnoea—Docetaxel—head and neck cancer	0.000525	0.00282	CcSEcCtD
Arformoterol—Somnolence—Docetaxel—head and neck cancer	0.000524	0.00281	CcSEcCtD
Arformoterol—Vomiting—Fluorouracil—head and neck cancer	0.000519	0.00278	CcSEcCtD
Arformoterol—Dyspepsia—Docetaxel—head and neck cancer	0.000518	0.00278	CcSEcCtD
Arformoterol—Rash—Fluorouracil—head and neck cancer	0.000515	0.00276	CcSEcCtD
Arformoterol—Dermatitis—Fluorouracil—head and neck cancer	0.000514	0.00276	CcSEcCtD
Arformoterol—Headache—Fluorouracil—head and neck cancer	0.000511	0.00274	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000509	0.00273	CcSEcCtD
Arformoterol—Fatigue—Docetaxel—head and neck cancer	0.000508	0.00272	CcSEcCtD
Arformoterol—Pain—Docetaxel—head and neck cancer	0.000504	0.0027	CcSEcCtD
Arformoterol—Constipation—Docetaxel—head and neck cancer	0.000504	0.0027	CcSEcCtD
Arformoterol—Feeling abnormal—Docetaxel—head and neck cancer	0.000485	0.0026	CcSEcCtD
Arformoterol—Nausea—Fluorouracil—head and neck cancer	0.000485	0.0026	CcSEcCtD
Arformoterol—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000482	0.00258	CcSEcCtD
Arformoterol—Abdominal pain—Docetaxel—head and neck cancer	0.000466	0.0025	CcSEcCtD
Arformoterol—Body temperature increased—Docetaxel—head and neck cancer	0.000466	0.0025	CcSEcCtD
Arformoterol—Hypersensitivity—Docetaxel—head and neck cancer	0.000434	0.00233	CcSEcCtD
Arformoterol—Asthenia—Docetaxel—head and neck cancer	0.000423	0.00227	CcSEcCtD
Arformoterol—Pruritus—Docetaxel—head and neck cancer	0.000417	0.00224	CcSEcCtD
Arformoterol—Diarrhoea—Docetaxel—head and neck cancer	0.000403	0.00216	CcSEcCtD
Arformoterol—Dizziness—Docetaxel—head and neck cancer	0.00039	0.00209	CcSEcCtD
Arformoterol—Vomiting—Docetaxel—head and neck cancer	0.000375	0.00201	CcSEcCtD
Arformoterol—Rash—Docetaxel—head and neck cancer	0.000371	0.00199	CcSEcCtD
Arformoterol—Dermatitis—Docetaxel—head and neck cancer	0.000371	0.00199	CcSEcCtD
Arformoterol—Headache—Docetaxel—head and neck cancer	0.000369	0.00198	CcSEcCtD
Arformoterol—Nausea—Docetaxel—head and neck cancer	0.00035	0.00188	CcSEcCtD
Arformoterol—CYP2A6—Fluoropyrimidine Activity—XRCC3—head and neck cancer	6.43e-05	0.0522	CbGpPWpGaD
Arformoterol—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	4.32e-05	0.0351	CbGpPWpGaD
Arformoterol—CYP2A6—Fluoropyrimidine Activity—DPYD—head and neck cancer	4.28e-05	0.0347	CbGpPWpGaD
Arformoterol—CYP2A6—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	4.07e-05	0.0331	CbGpPWpGaD
Arformoterol—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	3.94e-05	0.032	CbGpPWpGaD
Arformoterol—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	3.94e-05	0.032	CbGpPWpGaD
Arformoterol—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	3.59e-05	0.0291	CbGpPWpGaD
Arformoterol—CYP2A6—Xenobiotics—CYP1A1—head and neck cancer	3.41e-05	0.0277	CbGpPWpGaD
Arformoterol—CYP2A6—Tamoxifen metabolism—CYP1A1—head and neck cancer	3.28e-05	0.0266	CbGpPWpGaD
Arformoterol—CYP2A6—Fluoropyrimidine Activity—SMUG1—head and neck cancer	3.04e-05	0.0247	CbGpPWpGaD
Arformoterol—ADRB1—Melatonin metabolism and effects—CYP1A1—head and neck cancer	2.9e-05	0.0235	CbGpPWpGaD
Arformoterol—CYP2A6—Fluoropyrimidine Activity—TYMS—head and neck cancer	2.44e-05	0.0198	CbGpPWpGaD
Arformoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—head and neck cancer	2.42e-05	0.0197	CbGpPWpGaD
Arformoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	2.42e-05	0.0197	CbGpPWpGaD
Arformoterol—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	2.28e-05	0.0186	CbGpPWpGaD
Arformoterol—CYP2C19—Xenobiotics—CYP1A1—head and neck cancer	2.08e-05	0.0169	CbGpPWpGaD
Arformoterol—CYP2C19—Tamoxifen metabolism—CYP1A1—head and neck cancer	2e-05	0.0162	CbGpPWpGaD
Arformoterol—CYP2D6—Xenobiotics—CYP1A1—head and neck cancer	1.91e-05	0.0155	CbGpPWpGaD
Arformoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—head and neck cancer	1.91e-05	0.0155	CbGpPWpGaD
Arformoterol—CYP2C9—Xenobiotics—CYP1A1—head and neck cancer	1.89e-05	0.0154	CbGpPWpGaD
Arformoterol—CYP2D6—Tamoxifen metabolism—CYP1A1—head and neck cancer	1.84e-05	0.0149	CbGpPWpGaD
Arformoterol—CYP2C9—Tamoxifen metabolism—CYP1A1—head and neck cancer	1.82e-05	0.0148	CbGpPWpGaD
Arformoterol—CYP2C19—Melatonin metabolism and effects—CYP1A1—head and neck cancer	1.54e-05	0.0125	CbGpPWpGaD
Arformoterol—CYP2D6—Melatonin metabolism and effects—CYP1A1—head and neck cancer	1.42e-05	0.0115	CbGpPWpGaD
Arformoterol—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	1.42e-05	0.0115	CbGpPWpGaD
Arformoterol—CYP2A6—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	1.4e-05	0.0113	CbGpPWpGaD
Arformoterol—ADRB2—Arf6 trafficking events—CDH1—head and neck cancer	1.39e-05	0.0113	CbGpPWpGaD
Arformoterol—CYP2A6—Biological oxidations—NAT2—head and neck cancer	1.3e-05	0.0106	CbGpPWpGaD
Arformoterol—CYP2A6—NRF2 pathway—TGFA—head and neck cancer	1.26e-05	0.0102	CbGpPWpGaD
Arformoterol—CYP2A6—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	1.15e-05	0.00932	CbGpPWpGaD
Arformoterol—ADRB1—Endothelin Pathways—MAPK1—head and neck cancer	1.1e-05	0.00895	CbGpPWpGaD
Arformoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	1.09e-05	0.00881	CbGpPWpGaD
Arformoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—KISS1—head and neck cancer	1.06e-05	0.00862	CbGpPWpGaD
Arformoterol—ADRB2—Arf6 signaling events—EGFR—head and neck cancer	1.03e-05	0.00835	CbGpPWpGaD
Arformoterol—CYP2C19—Arachidonic acid metabolism—GPX1—head and neck cancer	1.01e-05	0.00819	CbGpPWpGaD
Arformoterol—CYP2C19—Arachidonic acid metabolism—CYP1A1—head and neck cancer	9.98e-06	0.00811	CbGpPWpGaD
Arformoterol—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	9.2e-06	0.00747	CbGpPWpGaD
Arformoterol—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	9.1e-06	0.00739	CbGpPWpGaD
Arformoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	8.94e-06	0.00726	CbGpPWpGaD
Arformoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GRP—head and neck cancer	8.74e-06	0.0071	CbGpPWpGaD
Arformoterol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	8.63e-06	0.00701	CbGpPWpGaD
Arformoterol—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	8.51e-06	0.00691	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—KISS1—head and neck cancer	8.27e-06	0.00671	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—KISS1—head and neck cancer	8.09e-06	0.00657	CbGpPWpGaD
Arformoterol—CYP2A6—Fluoropyrimidine Activity—TP53—head and neck cancer	8.08e-06	0.00656	CbGpPWpGaD
Arformoterol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	7.94e-06	0.00644	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—NAT2—head and neck cancer	7.94e-06	0.00644	CbGpPWpGaD
Arformoterol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	7.87e-06	0.00639	CbGpPWpGaD
Arformoterol—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	7.83e-06	0.00636	CbGpPWpGaD
Arformoterol—CYP2C19—Metapathway biotransformation—NAT2—head and neck cancer	7.83e-06	0.00636	CbGpPWpGaD
Arformoterol—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	7.76e-06	0.0063	CbGpPWpGaD
Arformoterol—CYP2A6—NRF2 pathway—GSTM1—head and neck cancer	7.33e-06	0.00595	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—NAT2—head and neck cancer	7.3e-06	0.00593	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—NAT2—head and neck cancer	7.24e-06	0.00588	CbGpPWpGaD
Arformoterol—CYP2D6—Metapathway biotransformation—NAT2—head and neck cancer	7.2e-06	0.00585	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	7.14e-06	0.0058	CbGpPWpGaD
Arformoterol—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	6.99e-06	0.00568	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—GRP—head and neck cancer	6.81e-06	0.00553	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—GRP—head and neck cancer	6.66e-06	0.00541	CbGpPWpGaD
Arformoterol—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	6.43e-06	0.00522	CbGpPWpGaD
Arformoterol—CYP2A6—Biological oxidations—GSTM1—head and neck cancer	6.43e-06	0.00522	CbGpPWpGaD
Arformoterol—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	6.38e-06	0.00518	CbGpPWpGaD
Arformoterol—CYP2A6—Biological oxidations—CYP1A1—head and neck cancer	6.09e-06	0.00495	CbGpPWpGaD
Arformoterol—CYP2C19—Arachidonic acid metabolism—PTGS2—head and neck cancer	5.94e-06	0.00482	CbGpPWpGaD
Arformoterol—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	5.41e-06	0.0044	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—UROD—head and neck cancer	5.36e-06	0.00435	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—KISS1—head and neck cancer	4.67e-06	0.00379	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—KISS1—head and neck cancer	4.57e-06	0.00371	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—KISS1—head and neck cancer	4.24e-06	0.00344	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—KISS1—head and neck cancer	4.15e-06	0.00337	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—GSTM1—head and neck cancer	3.92e-06	0.00318	CbGpPWpGaD
Arformoterol—CYP2C19—Metapathway biotransformation—GSTM1—head and neck cancer	3.87e-06	0.00314	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—GRP—head and neck cancer	3.85e-06	0.00312	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—GRP—head and neck cancer	3.76e-06	0.00306	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—CYP1A1—head and neck cancer	3.72e-06	0.00302	CbGpPWpGaD
Arformoterol—CYP2C19—Metapathway biotransformation—CYP1A1—head and neck cancer	3.66e-06	0.00298	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	3.6e-06	0.00293	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	3.57e-06	0.0029	CbGpPWpGaD
Arformoterol—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	3.56e-06	0.00289	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	3.52e-06	0.00286	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—GRP—head and neck cancer	3.49e-06	0.00284	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	3.42e-06	0.00278	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—GRP—head and neck cancer	3.42e-06	0.00277	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	3.39e-06	0.00275	CbGpPWpGaD
Arformoterol—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	3.37e-06	0.00274	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	3.34e-06	0.00271	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—UROD—head and neck cancer	3.27e-06	0.00265	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—UROD—head and neck cancer	3.01e-06	0.00244	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—UROD—head and neck cancer	2.98e-06	0.00242	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	2.54e-06	0.00206	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KISS1—head and neck cancer	2.51e-06	0.00203	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KISS1—head and neck cancer	2.45e-06	0.00199	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	2.31e-06	0.00188	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NAT2—head and neck cancer	2.23e-06	0.00181	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—GRP—head and neck cancer	2.06e-06	0.00168	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—GRP—head and neck cancer	2.02e-06	0.00164	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—STAT6—head and neck cancer	2e-06	0.00163	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—STAT6—head and neck cancer	1.96e-06	0.00159	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—DPYD—head and neck cancer	1.95e-06	0.00158	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—YAP1—head and neck cancer	1.85e-06	0.0015	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—YAP1—head and neck cancer	1.77e-06	0.00144	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—YAP1—head and neck cancer	1.73e-06	0.00141	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.44e-06	0.00117	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.43e-06	0.00116	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NAT2—head and neck cancer	1.36e-06	0.0011	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.31e-06	0.00107	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.3e-06	0.00106	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NAT2—head and neck cancer	1.25e-06	0.00101	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NAT2—head and neck cancer	1.24e-06	0.001	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—DPYD—head and neck cancer	1.19e-06	0.000966	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—YAP1—head and neck cancer	1.13e-06	0.000917	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—TYMS—head and neck cancer	1.11e-06	0.000903	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTM1—head and neck cancer	1.1e-06	0.000893	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—DPYD—head and neck cancer	1.09e-06	0.000889	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—DPYD—head and neck cancer	1.09e-06	0.000881	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GPX1—head and neck cancer	1.05e-06	0.000855	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP1A1—head and neck cancer	1.04e-06	0.000846	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—YAP1—head and neck cancer	1.04e-06	0.000843	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—YAP1—head and neck cancer	1.03e-06	0.000836	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—IL2—head and neck cancer	1.02e-06	0.000832	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—IL2—head and neck cancer	1e-06	0.000814	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL2—head and neck cancer	9.31e-07	0.000756	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL2—head and neck cancer	9.11e-07	0.000739	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	8.48e-07	0.000689	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NOTCH1—head and neck cancer	7.99e-07	0.000649	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NOTCH1—head and neck cancer	7.82e-07	0.000635	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	7.74e-07	0.000628	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—MAPK3—head and neck cancer	7.48e-07	0.000608	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	7.4e-07	0.000601	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—MAPK3—head and neck cancer	7.32e-07	0.000594	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—MAPK1—head and neck cancer	7.12e-07	0.000578	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—EGFR—head and neck cancer	7.12e-07	0.000578	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—MAPK1—head and neck cancer	6.96e-07	0.000566	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—EGFR—head and neck cancer	6.96e-07	0.000565	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CA—head and neck cancer	6.8e-07	0.000552	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—TYMS—head and neck cancer	6.78e-07	0.000551	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	6.75e-07	0.000548	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTM1—head and neck cancer	6.7e-07	0.000544	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CA—head and neck cancer	6.66e-07	0.00054	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GPX1—head and neck cancer	6.42e-07	0.000521	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1A1—head and neck cancer	6.35e-07	0.000516	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—TYMS—head and neck cancer	6.24e-07	0.000506	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTGS2—head and neck cancer	6.2e-07	0.000503	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—TYMS—head and neck cancer	6.18e-07	0.000502	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CA—head and neck cancer	6.18e-07	0.000502	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTM1—head and neck cancer	6.16e-07	0.000501	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTM1—head and neck cancer	6.11e-07	0.000496	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CA—head and neck cancer	6.04e-07	0.000491	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GPX1—head and neck cancer	5.9e-07	0.000479	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GPX1—head and neck cancer	5.85e-07	0.000475	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1A1—head and neck cancer	5.84e-07	0.000475	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1A1—head and neck cancer	5.79e-07	0.00047	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—HRAS—head and neck cancer	5.72e-07	0.000464	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—HRAS—head and neck cancer	5.59e-07	0.000454	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—AKT1—head and neck cancer	5.56e-07	0.000451	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL2—head and neck cancer	5.5e-07	0.000447	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—AKT1—head and neck cancer	5.44e-07	0.000442	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTEN—head and neck cancer	5.4e-07	0.000439	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL2—head and neck cancer	5.38e-07	0.000437	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCND1—head and neck cancer	5.36e-07	0.000435	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCND1—head and neck cancer	5.24e-07	0.000426	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.22e-07	0.000424	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PTEN—head and neck cancer	5.17e-07	0.00042	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PTEN—head and neck cancer	5.06e-07	0.000411	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—AKT1—head and neck cancer	5.05e-07	0.00041	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—AKT1—head and neck cancer	4.94e-07	0.000401	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	4.76e-07	0.000387	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—head and neck cancer	4.67e-07	0.000379	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—STAT3—head and neck cancer	4.63e-07	0.000376	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—head and neck cancer	4.57e-07	0.000371	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—STAT3—head and neck cancer	4.53e-07	0.000368	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK3—head and neck cancer	4.42e-07	0.000359	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK3—head and neck cancer	4.32e-07	0.000351	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK1—head and neck cancer	4.21e-07	0.000342	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGFR—head and neck cancer	4.21e-07	0.000341	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK1—head and neck cancer	4.11e-07	0.000334	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGFR—head and neck cancer	4.11e-07	0.000334	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CA—head and neck cancer	3.81e-07	0.00031	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTGS2—head and neck cancer	3.78e-07	0.000307	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CA—head and neck cancer	3.65e-07	0.000296	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CA—head and neck cancer	3.57e-07	0.00029	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—head and neck cancer	3.53e-07	0.000287	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTGS2—head and neck cancer	3.48e-07	0.000282	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—head and neck cancer	3.45e-07	0.00028	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTGS2—head and neck cancer	3.45e-07	0.00028	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HRAS—head and neck cancer	3.38e-07	0.000274	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HRAS—head and neck cancer	3.3e-07	0.000268	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTEN—head and neck cancer	3.3e-07	0.000268	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—AKT1—head and neck cancer	3.11e-07	0.000253	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTEN—head and neck cancer	3.03e-07	0.000246	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTEN—head and neck cancer	3e-07	0.000244	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT1—head and neck cancer	2.98e-07	0.000242	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT1—head and neck cancer	2.92e-07	0.000237	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CA—head and neck cancer	2.32e-07	0.000189	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CA—head and neck cancer	2.14e-07	0.000174	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CA—head and neck cancer	2.12e-07	0.000172	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AKT1—head and neck cancer	1.9e-07	0.000154	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKT1—head and neck cancer	1.75e-07	0.000142	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKT1—head and neck cancer	1.73e-07	0.000141	CbGpPWpGaD
